You are here

Alnylam

Alnylam, Sanofi given the all-clear to resume fitusiran trials

BioPharma Dive

Sun, 12/17/17 - 10:24 am

clinical trials

8 Takeout targets to watch in 2018

BioPharma Dive

Sat, 12/16/17 - 08:41 am

Bristol-Myers Squibb

Madrigal Pharmaceuticals

Spark Therapeutics

Four months after patient death, FDA’s hold lifted on Alnylam’s fitusiran

Endpoints

Fri, 12/15/17 - 09:32 am

FDA adds ‘breakthrough’ status for Alnylam as patisiran starts its victory lap at the agency

Endpoints

Mon, 11/20/17 - 07:45 pm

breakthrough status

Alnylam Starts Rolling NDA Submission for RNAi Candidate

Yahoo/Zacks.com

Fri, 11/17/17 - 11:15 am

hereditary ATTR amyloidosis

Alnylam outshines Ionis with RNAi drug

BioPharma Dive

Sat, 11/4/17 - 08:40 am

Ionis Pharmaceuticals

The Medicine Company's Dangerous Bet On Its LDL Cholesterol Lowering Drug

Forbes

Thu, 10/26/17 - 09:34 am

The Medicine Company

LDL cholesterol

PCSK9 inhibitors

With $500M-plus, a buyout and two new billion-dollar pacts, upstart Vir is ready to roll on infectious diseases

Endpoints

Wed, 10/18/17 - 10:08 am

Vir Biotechnology

A drug 15 years in the making: Alnylam's quest to prove RNAi

BioPharma Dive

Sat, 09/30/17 - 10:16 am

3 Biotech Stocks That Skyrocketed Last Week: Can They Go Higher?

Motley Fool

Mon, 09/25/17 - 09:42 am

Madrigal Pharmaceuticals

Arbutus BioPharma

Alnylam’s rare disease drug shines in trial, paving way for a brand-new class of medicines

Stat

Wed, 09/20/17 - 09:27 am

familial amyloid polyneuropathy

On Eve of Big Data Reveal, Patient Death Stalls Alnylam Hemophilia Drug

Xconomy

Thu, 09/7/17 - 05:46 pm

3 Biotech Stocks That Could Soar in September

Motley Fool

Sun, 08/27/17 - 06:26 pm

PTC Therapeutics

Alnylam review turns up no clear answers on revusiran deaths

BioPharma Dive

Thu, 08/10/17 - 06:53 pm

3 Drug Stocks Poised to Surpass Estimates in Q2 Earnings

Yahoo/Zacks.com

Wed, 08/9/17 - 09:41 am

Puma Biotechnology

Sanofi and Alnylam plunge into PhIII with a rival to Roche’s top hemophilia drug

Endpoints

Fri, 07/7/17 - 10:22 am

clinical trials

5 Biotech Stocks With Major Catalysts in July

Motley Fool

Wed, 06/28/17 - 11:03 pm

Puma Biotechnology

Alnylam lines up Phase 3 for another RNAi drug

BioPharma Dive

Tue, 06/27/17 - 10:33 am

acute hepatic porphyrias

5 Best Biotech Stocks of 2017 So Far

Motley Fool

Mon, 06/26/17 - 09:41 am

Puma Biotechnology

Sangamo BioSciences

Alnylam CEO’s pay fell nearly 80 percent in 2016

Bizjournals.com

Mon, 03/20/17 - 11:28 pm

John Maraganore

Pages